The US Supreme Court has temporarily lifted restrictions on the mail delivery of the abortion pill mifepristone, offering a short-term victory to abortion rights supporters while the legal battle continues.
The decision pauses a lower court ruling from the 5th Circuit Court of Appeals, which had imposed stricter regulations requiring patients to obtain the medication in person rather than through mail or telemedicine. By intervening, the Supreme Court has preserved broader access to the drug for now.
Mifepristone, approved by the Food and Drug Administration over two decades ago, is commonly used in combination with another drug to terminate early pregnancies. It accounts for more than half of all abortions in the United States, making its availability a critical issue in the country’s ongoing abortion debate.
The case stems from lawsuits filed by conservative groups and states seeking to roll back regulatory changes that expanded access to the drug, including allowing prescriptions via telehealth and delivery by mail. Opponents argue that these relaxed rules pose safety concerns, while medical experts and reproductive rights advocates maintain that the medication is safe and essential for access to care.
This temporary ruling does not settle the issue. Instead, it gives the Supreme Court time to review the legal arguments before issuing a final decision that could reshape abortion access nationwide.
The case is part of a broader legal and political struggle over reproductive rights in the United States following the landmark Roe v. Wade ruling being overturned in 2022. Since then, access to abortion has increasingly been determined by state-level laws, leading to a patchwork of regulations across the country.